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AbstrACt
Introduction A large proportion of malaria-infected 
individuals in endemic areas do not experience symptoms 
that prompt treatment-seeking. These asymptomatically 
infected individuals may retain their infections for many 
months during which sexual-stage parasites (gametocytes) 
are produced that may be transmissible to mosquitoes. 
Reductions in malaria transmission could be achieved 
by detecting and treating these infections early. This 
study assesses the impact of enhanced community case 
management (CCM) and monthly screening and treatment 
(MSAT) on the prevalence and transmissibility of malaria 
infections.
Methods and analysis This cluster-randomised trial 
will take place in Sapone, an area of intense, highly 
seasonal malaria in Burkina Faso. In total, 180 compounds 
will be randomised to one of three interventions: arm 
1 - current standard of care with passively monitored 
malaria infections; arm 2 - standard of care plus enhanced 
CCM, comprising active weekly screening for fever, and 
detection and treatment of infections in fever positive 
individuals using conventional rapid diagnostic tests 
(RDTs); or arm 3 - standard of care and enhanced CCM, 
plus MSAT using RDTs. The study will be conducted over 
approximately 18 months covering two high-transmission 
seasons and the intervening dry season. The recruitment 
strategy aims to ensure that overall transmission and force 
of infection is not affected so we are able to continuously 
evaluate the impact of interventions in the context of 
ongoing intense malaria transmission. The main objectives 
of the study are to determine the impact of enhanced CCM 
and MSAT on the prevalence and density of parasitaemia 
and gametocytaemia and the transmissibility of infections. 
This will be achieved by molecular detection of infections 
in all study participants during start and end season cross-
sectional surveys and routine sampling of malaria-positive 
individuals to assess their infectiousness to mosquitoes.
Ethics and dissemination The study has been reviewed 
and approved by the London School of Hygiene and 
Tropical Medicine (LSHTM) (Review number: 14724) and 
The Centre National de Recherche et de Formation sur le 
Paludisme institutional review board (IRB) (Deliberation 
N° 2018/000002/MS/SG/CNRFP/CIB) and Burkina Faso 
national medical ethics committees (Deliberation N° 2018-
01-010).
strengths and limitations of this study
 ► This study evaluates for the first time the impact 
of enhanced community case management (CCM) 
and monthly screening and treatment (MSAT) on the 
transmissibility of malaria from endemic populations 
to mosquitoes.
 ► The detailed examination of malaria infections, ga-
metocyte production and infectivity to mosquitoes 
across two peak transmission seasons and the in-
tervening low transmission season provides unique-
ly detailed information on the dynamics of parasite 
carriage and infectivity.
 ► Intensive monitoring of mosquito exposure in com-
bination with repeated assessments of parasite 
carriage in the human population allows detailed 
assessments of the force of malaria infection at 
different time points during the peak and low trans-
mission seasons.
 ► A limitation of this current study is that findings from 
this setting where malaria transmission intensity is 
high may not translate to areas of lower transmis-
sion intensity where the tested approaches may be 
used in malaria elimination efforts.
 ► The study specifically aims not to impact trans-
mission or maximise the community effect of the 
interventions. Rather, the study aims to quantify the 
impact of enhanced CCM and MSAT on the trajecto-
ry of infections experienced by the participating in-
dividuals, gametocyte production in these infections 
and transmissibility to mosquitoes.
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Findings of the study will be shared with the community via local 
opinion leaders and community meetings. Results may also be shared 
through conferences, seminars, reports, theses and peer-reviewed 
publications; disease occurrence data and study outcomes will be 
shared with the Ministry of Health. Data will be published in an online 
digital repository.
trial registration number NCT03705624.
IntroduCtIon
Malaria continues to be a major public health problem 
in sub-Saharan Africa. In 2017, there were an estimated 
435 000 deaths from malaria globally, 93% in sub-Saharan 
Africa.1 Despite this sobering figure and indications that 
no measurable reduction in global malaria cases has been 
achieved since 2015,1 many countries had experienced a 
considerable decline in malaria transmission prior to this2 3 
meaning malaria elimination and eradication are back 
on the agenda of the international research community 
and policy makers.4 5 To achieve this, interventions that 
specifically aim to reduce transmission of malaria para-
sites are high on the priority list of the research agenda 
for malaria eradication.6 7 Transmission of malaria begins 
with the formation of sexual-stage malaria parasites—the 
gametocytes. In Plasmodium falciparum infection, gameto-
cytes develop and mature in the bone marrow and first 
appear in the circulation 10–12 days after asexual para-
sites are detected.8 On release in circulation, male and 
female gametocytes may persist for several weeks after 
asexual parasites have been cleared. In chronic infec-
tions there is persistent (but fluctuating) production 
of gametocytes from their asexual progenitors.9 Once 
ingested by a blood-feeding female Anopheles mosquito, 
male and female gametocytes activate into gametes that 
fertilise and ultimately render the mosquito infectious to 
humans. Gametocytes are present in symptomatic malaria 
cases and in infections not accompanied by symptoms that 
are severe enough to elicit treatment-seeking behaviour—
so-called ‘asymptomatic infections’.10 Since these asymp-
tomatic infections represent a large proportion of all 
infections present in malaria-endemic settings,11 12 
asymptomatic parasite carriage may be a major compo-
nent of the human infectious reservoir for malaria.13–15 
Therefore detecting and treating these infections could 
be a valuable approach for reducing transmission. It is 
unclear how many asymptomatic infections start off as 
symptomatic infections and could potentially be detected 
and treated by enhanced community case management 
(CCM). With CCM, access to early diagnosis and treat-
ment is improved by community-based malaria diagnosis. 
CCM may involve the deployment of malaria posts that 
improve access to care while still relying on passive detec-
tion of infection or, in an enhanced format, may involve 
active screening for fever.16 17 In an optimistic scenario, 
CCM could be used to prevent the majority of infec-
tious days by abrogating infections before they become 
transmissible to mosquitoes. Alternatively, many incident 
infections may never elicit symptoms and would there-
fore remain undetected even during CCM with regular 
clinical examinations. In this situation, active screening 
approaches would be needed to identify asymptomatic 
infections for drug-based targeting to prevent or inter-
rupt the production of infectious gametocytes. Periodic, 
or monthly screening and treatment (MSAT) approaches 
aim to detect asymptomatic infections by screening popu-
lations regardless of symptoms. Their ability to detect all 
infections depends on the diagnostic used13 and in highly 
endemic settings the impact of MSAT may be transient.18 
The number of infections acquired and the likelihood 
that infections give rise to clinical symptoms may be influ-
enced by spatial and temporal variations in malaria expo-
sure.19 20 Thus, detailed entomological assessments may 
uncover small-scale variations in mosquito exposure that 
play a key role in determining the detectability and trans-
missibility of infections in a given area.21
In this study, we evaluate the impact of two intensi-
fied diagnostic and treatment strategies on the human 
infectious reservoir of malaria, and compare these to 
the current standard of care. These diagnostic and 
treatment strategies aim to (1) Detect and treat symp-
tomatic infections earlier and more comprehensively by 
enhanced CCM (weekly active screening for fever), and 
(2) Detect and treat asymptomatic malaria infections by 
monthly screening with point-of-care rapid diagnostic 
tests (RDTs) (MSAT).
MEthods And AnAlysIs
study design
This study is a cluster-randomised trial to determine the 
impact of two interventions on parasite carriage, gameto-
cyte carriage and infectiousness to mosquitoes. A total 
of 180 compounds (consisting of three to six enrolled 
participants) will be randomised to one of three study 
arms (60 compounds per arm): arm 1 - current standard 
of care with passively monitored malaria infections; 
arm 2 - standard of care plus enhanced CCM; or arm 
3 - standard of care and enhanced CCM, plus monthly 
screening and treatment (MSAT), as detailed in box 1.
The study will take place over approximately 18 months 
covering two high-transmission seasons and the low-trans-
mission season (dry season) in between. Throughout the 
study, entomological monitoring will take place to evaluate 
the local mosquito population and potential exposure to 
infected mosquitoes.
Gradual implementation of interventions
The aim of the study is to determine the ability of the 
interventions to detect malaria infections, and the 
transmission potential of these infections. To maximise 
coverage and ensure good adherence to intervention 
protocols the study will be implemented in two phases 
(figure 1). Phase I will initiate prior to the first trans-
mission season with 30 compounds enrolled per study 
arm. Phase II will initiate at the end of the first transmis-
sion season with an additional 30 compounds enrolled 
per study arm. Parasitology data and mosquito infection 
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box 1 study arms
Arm 1 (control): standard of care
 ► Standard of care with passively monitored malaria incidence at local 
health facilities. Health facilities will be equipped with research staff 
and adequate supplies to ensure malaria diagnosis and treatment 
with the first-line antimalarial artemether-lumefantrine (AL) accord-
ing to national guidelines.
 ► Seasonal malaria chemoprevention (SMC) in children <5 years 
of age implemented by the National Malaria Control Programme 
(monthly treatment with sulfadoxine-pyrimethamine + amodiaquine 
from July to October).
Arm 2 (intervention): community case management (CCM)
 ► Standard of care (as in arm 1).
 ► SMC (as in arm 1).
 ► Enhanced CCM for malaria involving weekly active screening for fe-
ver using a research-grade thermometer by a trained health worker. 
A measured temperature ≥37.5°C or reported fever in the last 24 
hours will prompt screening with a conventional rapid diagnostic 
test (RDT). RDT-positive individuals will be treated with AL according 
to national guidelines.
Arm 3 (intervention): CCM + monthly screening and 
treatment (MsAt)
 ► Standard of care (as in arms 1 and 2).
 ► SMC (as in arms 1 and 2).
 ► Enhanced CCM (as in arm 2).
 ► MSAT regardless of symptoms with a conventional RDT. Screening 
will be performed by research staff with 25–35 days between 
screening rounds; RDT-positive individuals will be treated with AL 
according to national guidelines.
data will be compiled and analysed before the start of 
the second transmission season (~May 2019), at which 
time sample size and study procedures may be amended 
upon ethical approval.
study setting
This study will be conducted within the Saponé health 
and demographic surveillance system (HDSS) area, 
located 45 km south-west of Ouagadougou, Burkina Faso. 
This HDSS is part of the INDEPTH Network (a global 
network of HDSS that provides a more complete picture 
of the health status of communities in low-income and 
middle-income countries) and covers a total popula-
tion of 85 000 living in 10 841 compounds. Compounds 
are georeferenced and a census of the population is 
conducted annually. The population is served by 23 local 
health facilities and a district hospital. This is a region 
of intense and highly seasonal malaria transmission 
(predominantly P. falciparum) with peak transmission 
from approximately June to October. Asexual parasite 
prevalence by microscopy in this population is ~50% in 
children below 15 years of age14 and studies in this and 
other malaria-endemic settings in Burkina Faso indicate 
that ~80% of all asexual parasite carriers have concurrent 
gametocytes at highly variable densities.14 22
Enrolment and randomisation
The unit of randomisation in this study is a compound. 
Per compound a minimum of one and maximum of two 
members will be enrolled from each of the three age 
groups (under 5 years of age, 5–15 years of age and over 
15 years of age), so that each compound will provide 
three to six enrolled participants. All participants must 
be willing to use the designated local health facilities, and 
to accommodate indoor and outdoor mosquito sampling 
for the study duration. Inclusion and exclusion criteria 
for individual study participants are listed in box 2. From 
the 2017 census data, an estimated 4700 compounds in 
the Saponé HDSS contained the required number of 
participants in each age category and are, in principle, 
eligible. Up-to-date census data will be used prior to the 
study to select eligible compounds for enrolment in the 
Sapone Marche and Pissy local health areas (figure 2). 
One hundred and eighty compounds will be enrolled and 
will be divided into 60 groups of three based on proximity. 
Within each group, one compound will be randomly 
allocated to each of the three study arms by a comput-
er-generated algorithm. To enable the impact of the 
interventions to be continually evaluated throughout the 
study period, the study is designed so that overall trans-
mission intensity is not influenced. To ensure the force of 
infection remains high ≤50% of all compounds in a given 
area will be enrolled in the study. This will be achieved by 
combining each group of three enrolled compounds with 
three non-enrolled adjacent compounds to form a total of 
60 groups (figure 3). Simulations predict that the inter-
ventions will have a very small impact on overall transmis-
sion in the study area relative to the current transmission 
intensity (figure 4).
Procedures
Study visits
At the start and end of each season, a cross-sectional 
survey will be performed concurrently in all enrolled 
compounds (online supplementary figure S1). These 
surveys will also include adults that are present in 
enrolled compounds but not participating in the inter-
ventions; additional informed consent will be obtained 
for this. In these surveys all individuals will have their 
axillary temperature measured and a finger prick blood 
sample taken for molecular assessment of gametocyte 
and parasite carriage (as detailed in table 1). In case of 
measured fever, the same finger prick blood sample will 
be used for malaria diagnosis by conventional RDT (first 
response malaria RDT, specific for P. falciparum and/or 
P. vivax, P. ovalae and P. malariae) and treatment will be 
offered as per national guidelines. Routine surveys will be 
conducted throughout the wet and dry seasons to assess 
parasite carriage, gametocyte carriage and infectivity to 
mosquitoes. These surveys will be performed on a subset 
of compounds each week on a rolling basis, so that each 
compound will be visited every 10 weeks. Finger prick 
blood samples will be taken and processed as detailed in 
table 1; one whole blood aliquot will be processed imme-
diately for molecular detection of P. falciparum parasi-
taemia by quantitative PCR (qPCR) targeting varATS.23 
qPCR-positive individuals (ie, those with parasites, not 
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Figure 1 Study flow diagram. Compounds are enrolled into the study during two phases of recruitment and randomised to 
the three study arms. CCM, enhanced community case management; LHF, local health facility; MSAT, monthly screening and 
treatment.
box 2 Inclusion and exclusion criteria for enrolled 
participants
Inclusion criteria
 ► Participants should be permanent residents of the compound.
 ► Participants should be willing to participate in repeated assessments 
of health and infection status and willing to donate a maximum of 
37 mL of blood (children <10 years of age) or 52 mL of blood (older 
individuals) during an 18-month period.
Exclusion criteria
 ► Any (chronic) illness that would affect study participation.
 ► Pre-existing severe chronic health conditions.
 ► Current participation in malaria vaccine trials or participation in such 
trials in the last 2 years.
 ► History of intolerance to artemether-lumefantrine.
necessarily gametocytes) will be invited to donate blood 
for mosquito-feeding assays. The maximum number of 
feeding assays per day will be dependent on logistical 
feasibility. Asymptomatic infections that are detected by 
PCR will not be treated if unaccompanied by malaria 
symptoms, in line with national treatment guidelines. 
Routine surveys will continue throughout the dry season 
to allow a detailed assessment of the number of newly 
acquired infections when minimal exposure to infected 
mosquito bites is assumed.
In all three arms, clinical malaria episodes will be 
passively monitored at the local health facilities. Partic-
ipants will be identified using study identity cards; for 
suspected malaria cases, temperature and clinical history 
will be recorded. Finger prick blood samples will be taken 
as detailed in table 1. Malaria diagnosis will be performed 
by RDT and infected subjects will be treated with arte-
mether-lumefantrine (AL). For infections detected by 
community health workers during enhanced CCM (arms 
2 and 3) or MSAT (arm 3) visits, the same procedure 
is used and samples are collected as detailed in table 1. 
For RDT or microscopy-positive infections detected at 
local health facilities or during the CCM or MSAT visits, 
when logistically feasible, the individuals will be invited 
to donate a blood sample for mosquito-feeding assays 
prior to treatment. For all mosquito-feeding assays blood 
samples will be collected and transported in a portable 
incubator or thermos flask to the insectary for direct 
membrane feeding assays (DMFAs).
Protected by copyright.
 o
n
 N
ovem
ber 4, 2019 at Radboud University Nijmegen.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030598 on 13 September 2019. Downloaded from 
5Collins KA, et al. BMJ Open 2019;9:e030598. doi:10.1136/bmjopen-2019-030598
Open access
Figure 2 Map of Sapone health and demographic surveillance system (HDSS) area with the selected study area highlighted in 
orange.
Entomology
Detailed assessments of mosquito exposure will be 
performed at the compound level. Mosquito exposure 
will primarily be determined using a CDC miniature light 
trap (Model 512; John W Hock Company, Gainesville, 
Florida, USA) placed inside one of the sleeping spaces 
close to the participants sleeping under a net. Sampling 
will be performed in every compound once every 14 
days, throughout the study. To explore outdoor biting 
and enable more sensitive sampling of sparse mosquito 
populations, human landing catches will be performed 
indoors and outdoors from dusk until dawn for a subset 
of compounds.24 Due to the low densities of mosquitoes 
present in the dry season, additional strategies will be used 
to optimise the potential for mosquito monitoring during 
that period. Dry season pyrethrum spray catches will be 
conducted in a selection of non-enrolled compounds to 
collect indoor resting mosquitoes. These compounds will 
be sprayed with the insecticide aerosol Kaltox (a mixture 
of pyrethroids and carbamate containing 0.27% alle-
thrin, 0.2% tetramethrin, 0.17% permethrin and 0.68% 
propoxur) for 30–45 s; dead and immobilised mosquitoes 
will be collected after 10 min. In addition, in the absence 
of water body larval habitats in the dry season an active 
search of refugia and resting trap collections may be 
performed close to study compounds. At all collections, 
factors such as housing type and presence of animals will 
be recorded and associations with mosquito exposure will 
be examined. Throughout the study, presence, size and 
location of water bodies will be periodically assessed.
Collected mosquitoes will be sorted and counted by 
sex and species using morphological characteristics, and 
classified according to blood feeding status and parity 
(unfed, blood-fed, semigravid and gravid) by micros-
copy. A subset of mosquitoes will be preserved for further 
molecular analysis.25 26 The age structure of the mosquito 
population will be determined by examination of tracheal 
distension within the ovaries.27 Infection status of Anoph-
eles caught in CDC traps will be determined using circum-
sporozoite ELISA28 29 and or PCR.30 31
Laboratory assessments
DMFAs will be performed to determine infectivity to 
locally reared female Anopleles coluzzii mosquitoes, as 
described previously.14 Whole blood collected in lithium 
heparin tubes will be offered in duplicate to 50–60 starved 
mosquitoes via an artificial membrane feeder (400–500 µl 
per feeder). Fully fed mosquitoes will be kept at 27°C–
29°C and maintained on a sucrose diet for approximately 
1 week (6–8 days). Mosquito infection will be determined 
by dissection and assessment for the presence and density 
of oocysts by two independent microscopists. Infected 
midguts will be stored for molecular confirmation of 
infection and genotyping for a subset of guts.14
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Figure 3 Study enrolment strategy. Health and demographic surveillance system census data were used to select eligible 
compounds based on the number and age of occupants. Eligible compounds were enrolled and groups of three enrolled 
compounds were combined with three non-enrolled compounds, generating 60 groups. Within each group the three enrolled 
compounds were randomly assigned to each of the three study arms. This strategy is used to ensure (1) An even spread or 
compounds in each arm over the study area. (2) That ≤50% of all compounds in the study area are enrolled in the study, so 
overall transmission intensity remains unaffected.
Figure 4 Interventions have minimal impact on overall 
transmission in the study area relative to transmission 
intensity. True prevalence of any malaria infection in 
simulations with study interventions (red) and without (blue) 
is similar. Simulated study activities begin in July 2018 and 
continue through the end of simulation. Lines indicate mean 
and shaded area the 95% observed interval across 25 
stochastic realisations.
Parasite DNA and RNA will be extracted from whole 
blood samples collected in EDTA tubes. Parasitaemia 
will be assessed using a qPCR assay targeting the var 
gene acidic terminal sequence (varATS qPCR)23 and 
gametocyte density and sex ratio will be assessed using 
established PCR protocols.32 Whole blood samples will 
be evaluated by highly sensitive (HS)-RDTs and presence 
and quantification of HRP2 will also be determined using 
the bead-based Luminex (Austin, Texas, USA) platform.33 
Multiplicity of infection will be determined in a selection 
of samples using merozoite surface protein (MSP)-geno-
typing34 or equivalent techniques.
Red blood cell polymorphisms that are associated 
with the likelihood of developing blood-stage (clin-
ical) malaria infection, the severity of malaria infection 
or gametocyte production (haemoglobin C, haemo-
globin S, α-thalassaemia and glucose-6-dehydrogenase 
deficiency)35 will be measured in baseline samples by 
multiplex luminex assay.36 In secondary analyses, anti-
body responses to parasite and gametocyte antigens 
will be determined by protein microarray37 and multi-
plex bead-based serological assays38 and associated with 
parasite carriage, clinical symptoms and infectivity. For 
a selection of samples functional transmission reducing 
immunity will be assessed by standard membrane 
feeding assay using plasma samples collected at the 
time of field-based DMFA.39
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Table 1 Sampling schedule; the table indicates the samples collected at each participant survey/visit
Sample type/procedure
Cross-
sectional 
survey
Routine 
survey
Passive case 
detection CCM MSAT DMFA
Axillary temperature and clinical 
assessment
X X X X X
Dried blood spot (DBS) X X X X* X
Whole blood in RNA protect X X X X* X X
Whole blood for DNA X X X X* X X
Rapid diagnostic test (RDT) X*   X X* X
Highly sensitive RDT (HS-RDT)           X
Plasma           X
Blood smear     X† X† X† X
*Sampling only takes place if the subject has fever or history of fever in the last 24 hours.
†Sampling only takes place if the subject has a history of antimalaria treatment in the previous 3 weeks for microscopic confirmation of 
malarial infection.
CCM, enhanced community case management; DMFA, direct membrane feeding assay; MSAT, monthly screening and treatment.
objectives/end points
The overall aim of the study is to determine the impact 
of the two diagnostic strategies on prevalence and trans-
missibility of infections. The hypothesis is that the para-
site prevalence and density are reduced in arms 2 and 3 
compared with the standard of care. More infections will 
be detected early and may therefore be abrogated before 
they develop into chronic asymptomatic infections with 
continuous gametocytaemia. As such the primary end 
point is parasite prevalence and density in each arm by 
molecular detection in the end of study cross-sectional 
survey. Secondary objectives and end points seek to eval-
uate the impact of the interventions after each season, 
and to define the contribution and infectivity of gameto-
cytes in these infections, as detailed in box 3. Exploratory 
objectives aim to understand the detectability and trans-
missibility of infections, by exploring (1) Relationships 
between parasitaemia and transmission, and (2) Associa-
tions between infectivity and host characteristics, parasite 
characteristics or mosquito exposure (box 3).
data analysis
For primary and secondary end points, parasite and 
gametocyte prevalences will be compared between 
arms using multivariate mixed-effects logistic regression 
models; parasite and gametocyte density will be assessed 
using multivariate mixed-effects linear regression models 
on log-transformed values. The number of incident infec-
tions will be assessed by Poisson regression and compared 
between arms. The proportion of infectious participants 
and proportion of infected mosquitoes will be assessed 
by logistic regression models. Analyses will take account 
of correlation of outcomes at the compound level and 
the matched randomisation scheme. There may be issues 
with convergence in mixed-effects models given the small 
number of subjects per compound. In this case, analysis 
based on compound level summaries will be performed. 
For exploratory end points, detected infections will be 
analysed in relation to the time and duration of infec-
tion, parasite and gametocyte prevalence and density, 
symptoms, complexity of infection, host characteris-
tics, mosquito exposure and infectiousness to mosqui-
toes. Parasite density will be related to detectability by 
HS-RDTs. The association between gametocyte density 
and mosquito infection prevalence and intensity will be 
determined using an established Bayesian hierarchical 
model that incorporates the density of male gametocytes 
and gametocyte sex ratio.40 In exploratory end points, 
model fitting will be performed for different strata of 
infection characteristics (eg, complexity of infection, 
concurrent asexual parasite density and season) and host 
characteristics (eg, antigametocyte immune responses, 
age). Mosquito exposure by indoor and outdoor trapping 
methods will be associated with the likelihoods of inci-
dent infections and opportunities to transmit infections 
using comprehensive malaria transmission models.41
sample size calculations and predicted impact of 
interventions
The hypothesis of the current study is that the para-
site prevalence is considerably reduced in arms 2 and 3 
compared with the standard of care. Assuming a conser-
vative parasite prevalence of 40% in the control arm, 
the current sample size should be sufficient to detect 
a twofold reduction in parasite prevalence with >99% 
power. This sample size will also allow us to detect the 
anticipated difference in the proportion of infections 
that are gametocyte-positive at the moment of detection 
(secondary objectives 3–5). We assume that ≥80% of all 
infections detected in cross-sectional surveys (ie, chronic 
asymptomatic infections) concurrently carry gameto-
cytes.14 We expect that infections that are detected by 
CCM or MSAT visits in arms 2 and 3 are of shorter dura-
tion and have lower gametocyte prevalence and density.15 
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box 3 objectives and end points
Primary objective/end point
 ► Parasite prevalence and density between arms by molecular detection 
at the end of the study cross-sectional survey (time frame: month 18 
(end of second transmission season; January–February 2020)).
secondary objectives/end points
 ► Parasite prevalence and density by molecular detection at the end 
of year 1 cross-sectional survey (time frame: month 6 (end of first 
transmission season; January–February 2019)).
 ► Parasite prevalence and density by molecular detection at the end of 
the dry season cross-sectional survey (time frame: month 12 (prior 
to second transmission season; June 2019)).
 ► Gametocyte prevalence and/or density by molecular methods at the 
end of study cross-sectional survey (time frame: month 18 (end of 
second transmission season; January–February 2020)).
 ► Gametocyte prevalence and/or density by molecular methods at the 
end of year 1 cross-sectional survey (time frame: month 6 (end of 
first transmission season; January–February 2019)).
 ► Gametocyte prevalence and/or density by molecular methods at the 
end of the dry season cross-sectional survey (time frame: month 12 
(prior to second transmission season; June 2019)).
 ► Gametocyte prevalence and/or density by molecular methods 
among Plasmodium falciparum infections during all visits in the 
study (time frame: throughout study, an average of 18 months).
 ► The number of incident infections/clinical incidence detected during 
community case management involving active weekly fever screen-
ing, monthly screening and treatment, and passive case detection 
(time frame: throughout study, an average of 18 months).
 ► Infectivity to mosquitoes of P. falciparum infections (time frame: 
throughout study, an average of 18 months).
Exploratory objectives/end points:
 ► The detectability of infections by highly sensitive rapid diagnostic 
tests (time frame: throughout study, an average of 18 months).
 ► The relationship between the proportion of infected mosquitoes and 
gametocyte density (time frame: throughout study, an average of 18 
months).
 ► The impact of infection characteristics on the transmissibility of infec-
tions to mosquitoes (time frame: throughout study, an average of 18 
months).
 ► The impact of human host characteristics on the transmissibility of 
infections to mosquitoes (time frame: throughout study, an average 
of 18 months).
 ► Association between total parasite density and gametocyte density 
(time frame: throughout study, an average of 18 months).
 ► Malaria transmission potential based on measured gametocyte densi-
ties and the association between gametocyte density and mosquito in-
fection rates (time frame: throughout study, an average of 18 months).
 ► Number of acquired clones based on genotyping (time frame: 
throughout study, an average of 18 months).
 ► The duration of infections in the dry season (time frame: months 
6–12, between end of season survey January/February 2019 and 
end of dry season survey June 2019).
 ► To quantify mosquito exposure in relation to incident infections and 
transmission opportunities (time frame: throughout study, an aver-
age of 18 months).
If we assume ≤50% gametocyte prevalence among 
these CCM/MSAT-detected infections, monitoring 100 
survey-detected and 100 CCM/MSAT-detected infections 
will result in 99% power to detect this difference (the 
calculations assumed a coefficient of variation of 0.5 and 
a significance level of 0.05).
Simulations predict that enhanced CCM will reduce 
asexual parasite carriage in arm 2 by 70%, 60% and 30% 
in children under 5 years, 5–15 years and adults >15 years, 
respectively. The addition of MSAT in arm 3 is predicted 
to have minimal impact in all age groups (figure 5). Simu-
lations were carried out in Epidemiological MODeling 
software (EMOD) V.2.1542 43 an agent-based model of 
malaria transmission using within-host infection, immu-
nity and infectivity dynamics41 44 calibrated to field data.45 
The study site census was gridded into 1 km grid cells 
with a total human population of 7800 individuals and 
birth and death rates of 39 per 1000 per year, resulting in 
17% of the population being under 5, and 25% between 
5 years and 15 years. Within a grid cell, the biting rate 
is surface area dependent but otherwise homogeneous. 
Humans moved between grid cells at a rate of one trip 
per person per year, and each trip lasted on average 2 
days. Vectors did not move between grid cells. Malaria 
dynamics are simulated in a highly seasonal setting with 
an annual entomological inoculation rate (EIR) of 150 
in the presence of insecticide treated bed nets (ITNs). 
Seasonality was based on entomology data collected in 
2011. The vector population was modelled as Anopheles 
gambiae mosquitoes with 65% anthropophily and 90% 
indoor feeding. All grid cells had the same seasonality 
and transmission intensity. For the simulations, the 
number of individuals per arm was ~165 during phase 
I until January 2019 when numbers increased by ~200 
individuals per arm for phase II. Means of 500 stochastic 
realisations are shown. Simulated interventions are as 
follows:
1. SMC: Administration of a curative drug with prophy-
lactic protection for 30 days to children<5 years. Four 
rounds of SMC carried out each year starting June 30 
with 30 days between rounds. Coverage was set at 80% 
per round and independent between rounds.
2. ITNs: Estimated age dependent distribution; 0–5 years=67%, 
5–10 years=74%, 10–15 years=68%, 15–20 years=65%, 
and >20 years=71%.
3. Passive case detection and health-seeking behaviour: AL ad-
ministered to uncomplicated and severe malaria cas-
es with age-dependent distance-based health-seeking. 
Distances to the two study health facilities in Sapone 
and Pissy were calculated from the centre of each grid 
cell with exponential half-distance in coverage of 10 
km. Maximum coverage was 50% for children under 
5 years, 30% for individuals over 5 years and 80% for 
severe cases. Patients received treatment within 3 days 
of onset of clinical symptoms.
4. Enhanced CCM in arms 2 and 3: Modelled as continu-
ous weekly active screening where fevers of 37.5°C or 
higher receive AL, beginning 30 June 2018 with 100% 
coverage.
5. MSAT with RDT in arm 3: Modelled as continuous 
monthly RDT testing (diagnostic sensitivity 40 asexual 
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Figure 5 Simulations predict the impact of interventions in arms 2 and 3 across age groups. Simulation of the impact of 
enhanced CCM (arm 2, green) and enhanced CCM+MSAT (arm 3, orange) relative to no intervention (arm 1, purple) on parasite 
carriage in young children, school-age children and adults. Lines indicate mean and shaded area the 95% observed interval of 
prevalence by PCR with sensitivity 4 parasites/µL across 500 stochastic realisations.
parasites/µL), with RDT-positive individuals receiving 
AL, beginning 30 June 2018 with 100% coverage.
Patient and public involvement
Patients and the public were not involved in the design 
of this study. The findings of the study will be shared 
with the community via the local opinion leaders. The 
project is followed by a community meeting to present 
some of the preliminary findings. Disease occurrence 
data will be shared periodically with the Ministry of 
Health and we will work closely with the National Malaria 
Control Programme. The results may also be shared in 
conferences, seminars, reports, theses and peer-reviewed 
publications.
EthICs
Ethical considerations
The purpose of the study and practical consequences of 
participation will be explained during both community 
meetings and visits to each household by experienced 
nurses. Objectives and procedures will be explained verbally 
and given in printed form in French or a local language. 
All compound members will be screened by a good clin-
ical practice (GCP)-trained clinician for enrolment criteria, 
signs of acute disease, and individual informed consent 
obtained (consent obtained from parent or legal guardian 
in the case of minors). Malaria infections will not be cleared 
prior to inclusion in the study but this may be considered 
later based on results of the first season. Payment will not be 
given for participation but instead participants will receive 
financial compensation for travel and time. In addition, 
each participant enrolled in the study will receive a free 
long-lasting insecticide-treated bed net and treatment for 
malaria and other common illnesses free of charge. The 
blood draw volumes will be minimised: a maximum of 6 mL 
of blood will be taken at any single time point and the total 
volume of blood taken during a 6-month period will be 
lower than 37 mL for individuals enrolled in arm 3, or lower 
than 22 mL for those in arms 1 and 2. Both the cumulative 
blood draw volume and maximum blood volume taken in 
a single sample are within the limits considered as physi-
ological ‘minimal risk’.46 No experimental medication is 
used in this study; AL is approved in the country as first-line 
antimalarial treatment. Study identification numbers will 
be used on all paper and electronic questionnaires. Some 
questionnaires will be programmed using OpenDat-
aKit with data entered into password-secured, encrypted 
tablets. Data will be uploaded daily to an encrypted cloud-
based sever. The current protocol version is 2.0 approved 
November 2018. Any modifications to the protocol which 
may impact on the conduct of the study, subject safety or 
potential benefit of the subjects, including changes of study 
objectives, study design, study procedures, study popula-
tion or sample size will require a formal amendment to the 
protocol. Such amendment will be approved by the ethics 
committees/IRB prior to implementation. The full WHO 
Trial Registration Data Set information is included in the 
online supplementary table S1. The trial was submitted to 
ClinicalTrials. gov( NCT03705624) prior to study initiation 
on the 19th July 2018. Delays in releasing the registration 
were related to minor textual changes required to adhere 
to  ClincalTrials. gov formatting requirements and did not 
change the content of the submission, but resulted in first 
release online in October.
trial oversight, monitoring and quality control
This study will comply with GCP guidelines and be conducted 
in accordance with the latest South African revision of the 
Declaration of Helsinki and local regulatory requirements. 
All study staff will receive a local workshop on GCP before 
the study starts. Since no experimental treatment is used 
in the study a data safety and monitoring committee will 
not be installed; a scientific steering committee will provide 
technical oversight and will assist with interpretation of 
data. The London School of Hygiene and Tropical Medi-
cine (LSHTM) is the research sponsor, taking responsi-
bility for the initiation and management of the clinical trial 
including trial monitoring. The LSHTM Research Gover-
nance and Integrity Office has reviewed, assessed and regis-
tered the trial and holds Public Liability (‘negligent harm’) 
and Clinical Trial (‘non-negligent harm’) insurance poli-
cies which apply to this trial.
Periodically, a subset of compounds will be randomly 
selected from each arm to be visited by the quality control 
team to monitor study implementation adherence and 
unintended effects of study interventions or conduct. 
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Quality control for mosquito-feeding assays includes regular 
enrolment of microscopy-positive gametocyte carriers as 
controls. For this, children aged 10–15 years from non-par-
ticipating compounds will be screened for the presence 
of gametocytes by microscopy and up to five gametocyte 
carriers will be enrolled every 6 weeks. Specific informed 
consent will be provided for this.
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